share_log

BioVie | 8-K: Current report

BioVie | 8-K: Current report

BioVie | 8-K：重大事件
美股SEC公告 ·  2024/10/24 16:20

Moomoo AI 已提取核心訊息

On October 23, 2024, BioVie Inc., a clinical-stage company focused on developing treatments for chronic debilitating conditions, announced the successful closing of a registered direct offering and a concurrent private placement. The offering involved the sale of 2,667,000 shares of Class A common stock at $2.25 per share, alongside warrants to purchase an equivalent number of shares at $2.12 per share. The gross proceeds from the offering amounted to approximately $6 million before deducting fees and expenses. BioVie intends to allocate the net proceeds for working capital and general corporate purposes. The shares were sold under a shelf registration statement previously filed with the SEC, and the warrants were offered in a private placement not subject to public offering registration requirements. ThinkEquity served as the sole placement agent for the transaction.
On October 23, 2024, BioVie Inc., a clinical-stage company focused on developing treatments for chronic debilitating conditions, announced the successful closing of a registered direct offering and a concurrent private placement. The offering involved the sale of 2,667,000 shares of Class A common stock at $2.25 per share, alongside warrants to purchase an equivalent number of shares at $2.12 per share. The gross proceeds from the offering amounted to approximately $6 million before deducting fees and expenses. BioVie intends to allocate the net proceeds for working capital and general corporate purposes. The shares were sold under a shelf registration statement previously filed with the SEC, and the warrants were offered in a private placement not subject to public offering registration requirements. ThinkEquity served as the sole placement agent for the transaction.
2024年10月23日，BioVie公司，一家專注於研發治療慢性疾病的臨床階段公司，宣佈成功完成一項直接發行註冊和同時進行的定向增發。該發行涉及以每股2.25美元的價格出售2,667,000股A類普通股，以及以每股2.12美元的價格購買相同數量股票的認股權證。發行籌集的總收入約爲600萬美元，在扣除費用和支出前。BioVie打算將淨收益用於運營資金和一般公司用途。這些股票是在此前向SEC提交的存貨註冊申報文件下出售的，認股證據是在一項不受公開發售登記要求約束的定向增發中發行的。ThinkEquity擔任本次交易的唯一放置代理商。
2024年10月23日，BioVie公司，一家專注於研發治療慢性疾病的臨床階段公司，宣佈成功完成一項直接發行註冊和同時進行的定向增發。該發行涉及以每股2.25美元的價格出售2,667,000股A類普通股，以及以每股2.12美元的價格購買相同數量股票的認股權證。發行籌集的總收入約爲600萬美元，在扣除費用和支出前。BioVie打算將淨收益用於運營資金和一般公司用途。這些股票是在此前向SEC提交的存貨註冊申報文件下出售的，認股證據是在一項不受公開發售登記要求約束的定向增發中發行的。ThinkEquity擔任本次交易的唯一放置代理商。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間